News Year None2021202020192018 October 18, 2021 Equillium Announces Two Abstracts Accepted for Presentation at the Upcoming Virtual 2021 American Society of Nephrology Annual Meeting September 30, 2021 Equillium Announces Multiple Abstracts Accepted for Presentation at ACR Convergence 2021 September 22, 2021 Equillium to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference September 8, 2021 Equillium to Present at the H.C. Wainwright 23rd Annual Global Investment Conference August 11, 2021 Equillium Announces Update to EQUALISE Study of Itolizumab in Patients with Systemic Lupus Erythematosus and Lupus Nephritis August 10, 2021 Equillium Reports Second Quarter 2021 Financial Results and Provides Clinical Development Update August 5, 2021 Equillium to Present at the BTIG Virtual Biotechnology Conference July 12, 2021 Equillium Announces Plans to Initiate Phase 3 Pivotal Study of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease Following End-of-Phase 1 Meeting with the FDA June 11, 2021 Equillium Announces Positive Topline Results from the EQUATE Study in First-line Treatment of Acute Graft-Versus-Host Disease June 10, 2021 Equillium Presents Data on Target Engagement and Modulation of CD6 on T Cells with Itolizumab at the International Society for Advancement of Cytometry Pagination Current page 1 Page 2 Page 3 Next page next › Last page last » Displaying 1 - 10 of 29
October 18, 2021 Equillium Announces Two Abstracts Accepted for Presentation at the Upcoming Virtual 2021 American Society of Nephrology Annual Meeting
September 30, 2021 Equillium Announces Multiple Abstracts Accepted for Presentation at ACR Convergence 2021
September 22, 2021 Equillium to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference
September 8, 2021 Equillium to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
August 11, 2021 Equillium Announces Update to EQUALISE Study of Itolizumab in Patients with Systemic Lupus Erythematosus and Lupus Nephritis
August 10, 2021 Equillium Reports Second Quarter 2021 Financial Results and Provides Clinical Development Update
July 12, 2021 Equillium Announces Plans to Initiate Phase 3 Pivotal Study of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease Following End-of-Phase 1 Meeting with the FDA
June 11, 2021 Equillium Announces Positive Topline Results from the EQUATE Study in First-line Treatment of Acute Graft-Versus-Host Disease
June 10, 2021 Equillium Presents Data on Target Engagement and Modulation of CD6 on T Cells with Itolizumab at the International Society for Advancement of Cytometry
